Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here’s Why

Core Viewpoint - BridgeBio Pharma, Inc. (NASDAQ:BBIO) is identified as a high growth healthcare stock with significant potential, particularly influenced by upcoming litigation and product developments [1][2]. Group 1: Price Target and Ratings - Mizuho raised the price target for BridgeBio from $91 to $106, maintaining an Outperform rating, citing the potential impact of Pfizer's tafamidis litigation scheduled for April 27 to May 5 [1]. - William Blair initiated coverage with an Outperform rating and a fair value estimate of $93.03 per share, highlighting the company's unique position and growth potential in the biotech sector [2]. Group 2: Product Development and Market Position - BridgeBio is a commercial-stage biopharmaceutical company focused on developing transformative medicines for genetic diseases and cancers [3]. - The company is experiencing an accelerating launch of its product Attruby, with regulatory submissions for infigratinib in achondroplasia planned for the second half of 2026, and new drug applications expected for late 2026 or early 2027 [2].